Get the Stockscreener App
18.51
3.79%
-0.73
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%What's Next? - MarketBeat
Viridian's Strategic Expansion: 527,750 Share Options Awarded as TED Programs Advance - StockTitan
Analyzing Ratios: Viridian Therapeutics Inc (VRDN)’s Financial Story Unveiled - The Dwinnex
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
This trade activity should not be overlooked: Viridian Therapeutics Inc (VRDN) - SETE News
Wells Fargo Downgrades Viridian Therapeutics Inc (VRDN) to an Equal weight from an Overweight - Knox Daily
SG Americas Securities LLC Purchases 14,644 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat
Moody Aldrich Partners LLC Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat
FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat
SG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Equities Analysts Offer Predictions for VRDN Q1 Earnings - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings? - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat
JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace
Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com
(VRDN) Investment Analysis - Stock Traders Daily
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8%Here's Why - MarketBeat
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLC - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Acquires 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Principal Financial Group Inc. Boosts Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Has $33.98 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value? - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Boosts Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 3.4%What's Next? - MarketBeat
Contrasting Viridian Therapeutics (NASDAQ:VRDN) and Zicix (OTCMKTS:ZICX) - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):